Australia Phenylketonuria Therapeutics Market Report 2023 to 2030

Australia Phenylketonuria Therapeutics Market Analysis

$ 3999

Australia Phenylketonuria Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for phenylketonuria therapeutics is being driven by a variety of factors, including the increasing prevalence of PKU, technological advancements in PKU diagnostics, government initiatives and funding, and growing patient demand for effective treatments for the condition. Major global players in Phenylketonuria Therapeutics Market are DAIICHI SANKYO COMPANY, LIMITED, Ajinomoto Cambrooke, Inc., American Gene Technologies, Ultragenyx Pharmaceutical, Nutricia, Homology Medicines, Inc., Reckitt Benckiser Group plc, Abbott, Travere Therapeutics, Inc., Synlogic, Promin., SOM BIOTECH, S.L. Healthcare, Synthetic Biologics, Inc., Nestl?, Codexis, BioMarin, Erytech Pharma.,

ID: IN10AURD058 CATEGORY: Rare Diseases GEOGRAPHY: Australia AUTHOR: Gaurav Bhongale

Buy Now

Australia Phenylketonuria Therapeutics Market Analysis Summary

Australia Phenylketonuria Therapeutics Market is valued at around $13.2 Mn in 2022 and is projected to reach $27.49 Mn by 2030, exhibiting a CAGR of 9.6% during the forecast period 2023-2030.

Phenylketonuria, a rare inherited disorder, causes the body to accumulate phenylalanine (PKU). Proteins are composed of amino acids. All proteins and a few artificial sweeteners include phenylalanine. Tyrosine is produced by your body using the enzyme phenylalanine hydroxylase and is required for the synthesis of neurotransmitters like adrenaline, norepinephrine, and dopamine. A mistake in the gene responsible for producing phenylalanine hydroxylase is the root cause of PKU. Your body is unable to break down phenylalanine if this enzyme is missing. Your body thus begins to accumulate phenylalanine. Preventing intellectual disability and serious health issues can be achieved by beginning treatment at a young age and continuing it throughout life.

The increased prevalence of phenylketonuria, the existence of medications in development, and growing public awareness of phenylketonuria are the main factors anticipated to propel the growth of the phenylketonuria market. Additionally, it is projected that the market for phenylketonuria will grow as a result of a rise in partnerships between the major market players and the growth and expansion of the healthcare sector. Major global players in Phenylketonuria Therapeutics Market are Daiichi Sankyo Company, Limited, Ajinomoto Cambrooke, Inc., American Gene Technologies, Ultragenyx Pharmaceutical, Nutricia, Homology Medicines, Inc., Reckitt Benckiser Group plc, Abbott, Travere Therapeutics, Inc., Synlogic, Promin., Som Biotech, S.L. Healthcare, Synthetic Biologics, Inc., Nestlé, Codexis, BioMarin, Erytech Pharma.

Market Dynamics

Market Drivers

The increased prevalence of phenylketonuria, the existence of medications in development, and growing public awareness of phenylketonuria are the main factors anticipated to propel the growth of the phenylketonuria market during the forecast period. Additionally, it is projected that the market for phenylketonuria will grow as a result of a rise in partnerships between the major market players and the growth and expansion of the healthcare sector. The increased research and commercialization of new medications as well as advancements in the healthcare sector will also provide favourable prospects for the expansion of the phenylketonuria market in the years to come.

Market Restraints

The phenylketonuria industry is also being constrained by rising treatment prices and stringent government regulations. However, in the near future, there may be further barriers to the growth of the phenylketonuria market due to the lack of knowledge among patients and physicians.

Key players

BioMarin Pharmaceutical Inc. Pfizer Sanofi Shire plc Catalyst Biosciences uniQure Ionis Pharmaceuticals Alnylam Pharmaceuticals Intercept Pharmaceuticals Novartis

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Australia Phenylketonuria Therapeutics Market

By Type

classic phenylketonuria
mild phenylketonuria
benign phenylketonuria.

By Drugs

Kuvan
Playnziq
Other Drugs

By Therapy

Gene therapy
Dietary therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.